New drug slows breast cancer growth by 14 months

Treatment, approved for several types of breast cancer, garners $3.8b sales last year

3m read
In results reported at the meeting on Monday, patients who got Enhertu in combination with a standard medicine called pertuzumab lived for almost 41 months before their disease spread.

LOAD MORE

TRENDING STORIES